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ABSTRACT 
 
The main purpose of this thesis was to identify and further specify factors relevant for the 
assessment of fracture risk. The studies were conducted on two different cohorts of elderly 
women. The Osteoporosis Prospective Risk Assessment study (OPRA) is a cohort of women 
followed for over a decade, from the age of 75. The Distal Forearm Fracture study (DFF) is a 
cross-sectional cohort of postmenopausal women with a distal forearm fracture and age-
matched controls, with a mean age of 65.  
Even though the mortality among individuals that declined participation in the OPRA study 
was increased, it appeared that participants were fairly representative in terms of fracture risk 
in general. In the OPRA cohort, self-reported history of fall corresponded to increased risk of 
distal forearm and any osteoporosis-related fracture. Decreased gait speed and a failed 
balance test corresponded to increased hip fracture risk. Current smokers had an increased 
risk of vertebral and any osteoporosis-related fracture. Smoking cessation reduced the risk of 
vertebral fracture. Time as a smoker corresponded to increased vertebral fracture risk. 
However, amount smoked and time from cessation did not affect fracture risk. In the DFF 
cohort, women with fracture had decreased site-specific volumetric trabecular and cortical 
BMD, as well as geometric alterations with increased size and decreased cortical thickness. 
Weak correlations between parathyroid hormone levels and 25-hydroxy vitamin D with 
cortical and trabecular bone were observed. Out of 161 women with a distal forearm fracture, 
13 women (8%) were diagnosed with primary hyperparathyroidism, suggesting a higher 
prevalence than in the general population.   
In summary, external validity in studies on fracture risk may be satisfactory. It appears to be 
of great importance to consider physical function and smoking habits in elderly women in the 
fracture risk assessment. In addition, both trabecular and cortical bone reductions as well as 
geometric alterations of the forearm may be contributing factors in the pathogenesis of a 
distal forearm fracture. The occurrence of primary hyperparathyroidism appears to be high in 
women with a distal forearm fracture, suggesting that further evaluation following a low-
energy distal forearm fracture might be beneficial.  
  
SAMMANFATTNING 
 
Osteoporos är en vanlig skelettsjukdom som kännetecknas av minskad skelettstyrka och ökad 
frakturrisk. Risken för att drabbas av en fraktur ökar med åldern och postmenopausala 
kvinnor är särskilt drabbade på grund av sjunkande nivåer av östrogen. Osteoporosrelaterade 
frakturer (handledsfraktur, höftfraktur, kotkompression) är förknippade med mycket lidande 
och kan även innebära ett förkortat liv. Det finns effektiv behandling som stärker skelettet 
och därför är det viktigt att identifiera kvinnor som har en ökad frakturrisk. Huvudsyftet med 
den här avhandlingen var att identifiera och ytterligare specificera faktorer som är relevanta 
vid frakturriskbedömningen.  
Studierna genomfördes på två olika studiegrupper: en observationsstudie i Malmö som består 
av kvinnor som följts i över ett decennium från 75 års ålder och en tvärsnittsstudie av kvinnor 
med och utan handledsfraktur med en medelålder på 65 år. 
Vi undersökte om kvinnor som valt att delta i observationsstudien var representativa även för 
de som avstått. Dödligheten bland kvinnorna som avstått att delta var högre än vad den var 
bland de som deltog, men deltagarna var trots det relativt representativa när det kom till 
frakturrisken. I en annan studie fann vi att förekomsten av ett fall det senaste året innebar en 
ökad risk för att drabbas av en handledsfraktur, eller en osteoporosrelaterad fraktur. En 
nedsatt gånghastighet eller ett misslyckat balansprov medförde en ökad risk för att drabbas av 
en höftfraktur. Vi såg att rökare hade en ökad risk för att drabbas av en kotkompression, eller 
en osteoporosrelaterad fraktur. Att ha slutat röka minskade risken för en kotkompression.  
Kvinnor med en handledsfraktur hade en nedsatt trabekulär och kortikal skelettdensitet. De 
hade även geometriska förändringar med en ökad omkrets av strålbenet, kombinerat med en 
minskad kortikal tjocklek. Både paratyreoideahormon och D-vitamin korrelerade svagt med 
kortikalt och trabekulärt skelett. Av 161 kvinnor med en handledsfraktur diagnosticerades 13 
(8%) med primär hyperparatyreoidism, vilket antyder att det hos denna grupp är vanligare än 
hos den allmänna befolkningen. 
Sammanfattningsvis verkar överförbarheten av resultaten i studier som handlar om frakturrisk 
vara tillfredsställande. Det förefaller vara viktigt att ta hänsyn till rökvanor och att bedöma 
den fysiska förmågan hos äldre kvinnor när frakturrisken bedöms. Både minskningar av 
trabekulärt och kortikala skelett, såväl som geometriska förändringar kan vara bidragande 
faktorer vid uppkomsten av en handledsfraktur. Förekomsten av primär hyperparatyreoidism 
  
kan vara hög hos kvinnor med en handledsfraktur vilket antyder att det kan vara fördelaktigt 
med ytterligare uppföljning och utredning efter en handledsfraktur. 
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1 INTRODUCTION  
Osteoporosis is a common systemic bone disease characterized by reduced bone strength and 
increased fracture risk. The risk of contracting a fracture increases with age and 
postmenopausal women are particularly affected. A fracture may be associated with short 
term disability, but may also result in permanent disability or even a shortened life-span. 
Effective treatment that strengthens bone and reduces fracture risk is available and identifying 
those at risk is therefore of interest, both for the individual and society at large. Fracture risk 
is dependent on bone properties, such as mass and structure, but also on factors not related to 
bone. To introduce the reader to the papers in this thesis here follows a description of bone, 
osteoporosis, risk factors for fracture and measurements of bone mass and structure.  
2 BACKGROUND 
2.1 BONE 
The main functions of bones in the human body are mechanical and metabolic. Bones 
provide structure, stability and protection while at the same time remaining low weight and 
facilitating movement by the attachment of muscles, tendons and ligaments. Furthermore, 
bone serves as a reservoir for calcium and phosphate and plays an important role in the 
calcium homeostasis. Bone also interacts with the hematopoiesis in the bone marrow (1, 2).  
To comply with the mechanical and metabolic needs, the bone tissue is constantly being 
remodeled by bone removal and new bone formation. Through the remodeling process, bone 
is renewed and through modeling, bone is reinforced at skeletal sites with high mechanical 
load. In addition, the remodeling process allows for regulation of the calcium homeostasis. 
Through various mediators, low concentration of serum calcium stimulates bone resorption, 
resulting in a release of calcium from bone, at the expanse of bone mass. Consequently, the 
integrity of the bone is a result of both mechanical and the metabolic functions (1). 
2.1.1 Organization 
On a macroscopic level, bone is organized in terms of cortical and trabecular bone (Figure 1). 
Cortical bone is the more compact outer layer of the bone while trabecular bone is the more 
porous inner portion. Trabecular bone consists of a network of rods and plates, which is 
surrounded by bone marrow. Because of different mechanical requirements in different parts 
of the body, bones vary in size, shape and constitution. The proportion of cortical and 
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trabecular bone vary in different skeletal sites. The metaphysis and epiphysis of long bones in 
arms and legs mainly consists of trabecular bone. Trabecular bone is also the main 
component of the vertebral body and pelvis. The diaphysis of long bones mainly consists of 
cortical bone with a central hollow part, which is mainly comprised by bone marrow (1, 2).                      
     
The outer contour of the bone, except parts with cartilage or sites for attachment of tendons 
and ligaments, is covered by a membrane called periosteum. The periosteum consists of an 
outer fibrous layer that is rich in nerve fibers and blood supply. The inner layer of the 
periosteum is called cambium and consists mainly of progenitor cells, which have the ability 
to differentiate into bone forming osteoblasts (Chapter 2.1.3) (1, 2).  
2.1.2 Histology 
Bone tissue consists of a matrix of non-organic and organic matter, surrounding small 
amounts of cells. The organic matter of the matrix consists mainly of type I collagen 
molecules, arranged in fibrils that cross-link and form type I collagen fibers. The non-organic 
matter of the matrix is comprised of crystalized mineral salts, mainly hydroxyapatite, which 
is deposited in the collagen fibers in a calcification process. Hydroxyapatite is a crystalline 
complex of calcium and phosphate with the formula: Ca10(PO4)6(OH)2. While the collagen 
fibers contribute to the flexibility and tensile strength of the bone, the hydroxyapatite 
provides stiffness. In addition, the matrix consists of water and small amounts non-
collagenous proteins (1, 3). 
In the adult cortical bone, the calcified collagen fibers are organized into parallel arranged 
lamellae, which form a cylindrical structural unit called osteon (Figure 2). Each osteon entails 
a central cavity called, the Haversian canal, which contains blood vessels and nerve fibers, 
Figure 1. Cortical and Trabecular bone at the hip (By 
Eranicel. Published with permission from Shutterstock) 
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which is surrounded by concentric rings of lamellae. The lamellae and osteons are mainly 
arranged in the direction of the bones vertical axis. Additional traversing canals, Volkmann´s 
canals, facilitate connections between Haversian canals and the cortical surface. The lamellae 
in trabecular bone do not form osteons but are arranged concentric in line with each trabecula 
(1).   
 
 
 
2.1.3 Cells 
The main cells found in bone, responsible for bone formation and remodeling are: 
osteoblasts, osteocytes, lining cells and osteoclasts (Figure 3).  
Osteoblasts are mononucleated cuboid cells derived from the mesenchymal stem cell lineage. 
The differentiation into osteoblast is controlled by several regulatory factors. Runx2 and 
osterix are the two most essential transcription factors. Osteoblasts synthesizes and secretes 
osteoid, consisting predominately of type I collagen and non-collagenous proteins. In 
addition, osteoblasts produce hydroxyapatite by precipitation of calcium and phosphate (1).  
Osteocytes are the continued differentiation of osteoblasts after encasement in bone matrix. 
They are the most commonly found cells in bone tissue. Osteocytes reside between the 
lamellae in lacunae, and communicate to surface lining cells and osteoblasts trough dendritic 
processes in canaliculi (Figure 2). By registration of mechanical stress through integrin 
receptors, the osteocytes are believed to play an important role in the adaptation of bone 
remodeling to changes in mechanical forces (4, 5). 
Figure 2. Osteon. (By Mmutlu. Published with 
permission from Shutterstock) 
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Lining cells are flat cells derived from osteoblasts, covering inactive bone. Lining cells are 
equipped with receptors for various agents and communicate with osteocytes within the bone. 
When stimulated, the lining cells can induce bone remodulation (1). 
Osteoclasts are large multinucleated cells derived from the hematopoietic cell lineage. 
Osteoclasts are differentiated from macrophage cells and the differentiation is dependent on 
the presence of the cytokine, Receptor Activator of Nuclear factor Kappa-β Ligand 
(RANKL). The binding of RANKL to the receptor called, Receptor Activator of Nuclear 
factor Kappa-β (RANK) on preosteoclasts initiates differentiation and activation. Conversely, 
Osteoprotegerin (OPG) is a receptor that inhibits osteoclast differentiation and activation by 
binding to RANKL, and thereby preventing RANKL from binding to RANK.  
The osteoclasts adhere to bare bone surface and forms a tight seal with a capsuled 
compartment between the cell and the bone matrix (resorptive pit). The release of acid into 
the resorptive pit by proton ATPase dissolves the hydroxyapatite into calcium and phosphate. 
In addition, proteases are released into the resorptive pit through lysosomes, which degrades 
the collagen matrix (1, 6).   
2.1.4 Remodeling  
Bone remodeling refers to the process of bone formation and resorption (Figure 3). By 
remodeling, the bone maintains strength by removing and replacing old bone tissue with new 
bone. Trough remodeling, the bone can also maintain systemic calcium homeostasis (1). 
  
 
   
Bone remodeling occur at the bone surface which in cortical bone corresponds to either the 
endosteal or periosteal surface, or within a Haversian and Volkmann canal. Upon activation, 
preosteoclasts are recruited and differentiated to osteoclasts. Following attachment to the 
bone surface the osteoclasts resorb bone matrix. In cortical bone, this process creates a 
Figure 3. Bone cells and the remodeling process (By Designua. Published with 
permission from Shutterstock) 
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conical hole wherein a capillary vessel grows, supplying osteoblast progenitor cells that 
differentiate to osteoblasts. The whole is filled with bone matrix and the result is a new 
osteon. In trabecular bone, remodeling occurs on the trabecular surface (1, 7).   
The remodeling process is continuous and the turnover rate (the rate in which bone is being 
replaced) differs between skeletal sites. Turnover rate is higher in central skeletal sites such as 
the vertebral body and pelvis compared to peripheral skeletal sites, and is generally higher in 
trabecular bone compared to cortical bone. This is due to the construction of the trabecular 
network, which entails a larger surface area for remodeling (1).  
Bone modeling is the process in which the bone adapts to changes in mechanical loading and 
is less continual in adults (1).  
2.2 BONE AND THE CALCIUM HOMEOSTASIS   
The maintenance of blood and extracellular fluid calcium concentration within a 
physiological range is referred to as the calcium homeostasis. The concentration of calcium in 
blood is equivalent to that of most extracellular spaces. However, it is considerably lower 
intracellularly. In blood, calcium occurs either as ionized calcium, complexed to anions or 
protein-bound, predominately to albumin. Around half of the total calcium in blood is ionized 
calcium, which is the biological active form and therefore under regulatory control. 
Measurements of total blood serum calcium concentration are influenced by the amount of 
circulating albumin, and when estimating the amount of biological active calcium, 
adjustments for albumin concentration is required. Physiological concentration of serum 
ionized calcium is essential for the normal functioning of several biological processes such as 
blood coagulation, muscle contraction and nerve conduction, as well as in maintaining 
cellular integrity. Bone is the most important reservoir of calcium in the human body (8, 9).  
2.2.1 Regulation of the calcium homeostasis 
The calcium homeostasis is regulated by parathyroid hormone (PTH), calcitonin and the 
active form of vitamin D (1,25 (OH)2D, calcitriol). The three hormones maintain homeostasis 
by a series of synergic and negative feedback mechanisms, affecting primarily the intestinal 
tract, kidney and bone.  
2.2.2 Parathyroid hormone 
The parathyroid glands are sensitive for small changes in ionized calcium concentrations. 
Calcium sensing receptors on the parathyroid gland cell membrane react immediately to 
changes in ionized calcium levels and decreasing levels activate a signaling pathway, 
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resulting in the release of PTH to the circulation. The biological active intact PTH is cleaved, 
predominately in the liver, producing inactive fragments. The inactive PTH fragments are 
cleared by the kidneys and have a significant longer half-life than intact PTH (10). There are 
two main receptors for PTH; the PTH1R receptor is found in bone and kidney tissue, while 
the PTH2R receptor is found mainly in the nervous system (11, 12). 
PTH increases the concentration of ionized calcium by: (i) increasing reabsorption of calcium 
in the kidneys by a direct effect on the proximal renal tubule, simultaneously increasing the 
renal phosphate excretion, (ii) stimulating osteoclast activity which increases the release of 
ionized calcium from bone, and (iii) activating the enzyme 1α-hydroxylase in the proximal 
renal tubule, which in turn increases the activation of vitamin D (Chapter 2.2.4) (10).  
The effects of PTH on osteoclast activity are mediated through an increased RANKL 
expression, thereby stimulating the differentiation and activity of osteoclasts. Continuously 
increased PTH levels have catabolic effects on bone (10).  
2.2.3 Calcitonin 
Calcium sensitive C cells in the thyroid gland releases calcitonin in response to elevated 
levels of ionized calcium. Calcitonin decreases ionized calcium levels by inhibiting osteoclast 
activity and decreasing tubular resorption of ionized calcium in the kidneys (13).  
2.2.4 Vitamin D 
There are three sources of vitamin D; the skin, diet and dietary supplements. The skin is the 
most important contributor. In the diet, vitamin D is mainly found in fatty fish. In some 
countries, vitamin D is also supplemented in dairy products. In the skin, 7-dehydrocholesterol 
is transformed by UV-B rays from sunlight, causing the formation of pre-vitamin D, which in 
turn under the influence of skin temperature, is converted to cholecalciferol (vitamin D). 
Cholecalciferol is the precursor of active vitamin D (calcitriol) and the activation process 
involves hydroxylation of carbon atoms in two steps, in the liver and kidney respectively. In 
the liver, the hydroxylation of carbon 25 is facilitated by the enzyme cytochrome P450, 
resulting in 25(OH)D. The second hydroxylation, of carbon 1, is facilitated by the enzyme 
1α-hydroxylase (which is activated by PTH) in the kidney, resulting in the active vitamin D 
hormone 1,25(OH)2D, calcitriol. In this text, the active hormone calcitriol is simply referred 
to as vitamin D (14, 15).  
Vitamin D circulates bound to vitamin D binding protein (DBP) and the target receptors 
(VDR) are mainly located in the renal and intestinal epithelia as well as in bone. The main 
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mechanisms of vitamin D are regulation of calcium and phosphate metabolism, and the 
furtherance of normal bone mineralization. However, VDR´s have been found in a variety of 
tissues, emphasizing the possible widespread effects of vitamin D (14, 15). 
Vitamin D acts mainly by increasing intestinal absorption of calcium by stimulating calcium 
channels, calcium-transporting proteins (calbindins) and calcium pumps in the small intestine 
and duodenum. Furthermore, vitamin D increases the reabsorption of calcium in the kidney 
tubules with similar mechanism as in the intestine (16).   
2.3 AGE-RELATED BONE CHANGES 
The skeletal growth during childhood and adolescence results in rapidly increasing bone 
mass. In the years following puberty, skeletal maturation is achieved and is defined as peak 
bone mass (Figure 4). A variety of factors influence the degree of bone growth during 
childhood and adolescence, including heredity, diet, disease, physical activity and smoking. 
Moreover, influences during intrauterine life seem to have an impact on peak bone quality 
and mass (17). The peak bone mass is greater in men compared to women, which is primarily 
explained by an increased bone size in men (17-21).  
 
 
   
After adolescence, bone mass decreases continuously with deteriorations of both cortical and 
trabecular bone. The established peak bone mass and size is therefore important in 
determining future bone mass. Trabecular network deterioration results in fewer and thinner 
trabeculae while cortical deterioration entails a reduced cortical thickness and increased 
cortical porosity. However, the reductions of material properties are somewhat compensated 
for by geometric alterations. Endosteal resorption in combination with periosteal apposition 
Figure 4. Age and bone mass (By Anatomy & Physiology. Connexions Web site, via 
Creative Commons)             
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of the cortical shell increases the bone size. The resulting increased cross sectional area, with 
a displacement of the cortical shell from the central axis, provides a greater resistance to load. 
In men, periosteal apposition is greater, which is believed to be a contributing factor to the 
greater bone strength in men (18, 19, 21, 22).   
2.4 OSTEOPOROSIS 
 
 
 
 
Osteoporosis is, according to the National Institutes of Health (NIH), defined as “a skeletal 
disorder characterized by compromised bone strength predisposing a person to an increased 
risk of fracture”. Furthermore, bone strength is described as dependent on two bone 
properties; bone density and quality (such as microarchitecture and rate of remodulation) 
(23). The World Health Organization (WHO) defines osteoporosis solely by areal bone 
mineral density (aBMD), measured with Dual-energy X-ray absorptiometry (DXA) (Chapter 
2.6.1) (24).  
As a clinical diagnostic criterion, the measured areal BMD in a specific patient must be 
compared to a healthy reference population. Due to measurement differences between DXA 
devices, the actual aBMD measurements are standardized and changes are described as 
standard deviations (SD) from the mean. In postmenopausal women and men over the age of 
50, the measured aBMD is compared to the young (20-29 years) reference population mean, 
and the SD is referred to as T-score. In premenopausal women and younger men, the aBMD 
is compared to the age-matched mean, and referred to as Z-score (23-25).  
The WHO diagnostic criterion for osteoporosis is a decrease of 2,5 standard deviations or 
more (T-score ≤ -2.5) of the total hip, femoral neck or lumbar spine (23, 25).     
Figure 5. Normal vertebra and osteoporotic vertebra (By Turner Biomechanics 
Laboratory, via Creative Commons)   
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2.4.1 Primary osteoporosis  
In women, a rapid predominately trabecular bone loss occurs during menopause because of 
declining estrogen levels. Estrogen has several effects on bone remodulation and is a strong 
determinant of bone mass. The bone anabolic effect of estrogen is mediated by a suppression 
of RANKL, caused by a high OPG production, resulting in an inhibition of osteoclast 
differentiation and activity. In addition, estrogen inhibits osteoclast activity by direct 
mechanisms and through several other cytokines and growth factors. The rapid 
postmenopausal bone loss levels out after 4-8 years and is followed by continued gradual 
deterioration (Figure 4) (18, 19, 22).  
2.4.2 Male osteoporosis 
Men do not suffer from a rapid bone loss as women do during menopause. However, 
declining levels of testosterone and estrogen during ageing is believed to contribute to bone 
loss in elderly men. In men with osteoporosis, 50% suffer from secondary osteoporosis 
compared to about 25 % in women (18, 19, 22). 
2.4.3 Senile osteoporosis 
Contributing to bone fragility in the elderly is declining levels of active vitamin D due to less 
production in the skin and reduced ability to activate vitamin D in the kidneys and liver. The 
resulting negative calcium balance triggers secondary increments of PTH (Secondary 
hyperparathyroidism, SHPT) which, combined with decreased nutrition and degenerative 
muscle loss (sarcopenia), further deteriorates the bone (18, 19, 22, 26-28). 
2.4.4 Secondary osteoporosis 
Several medical conditions and pharmaceuticals affect bone remodeling and may 
consequently lead to the development of secondary osteoporosis. Some of the most prevalent 
are listed in Table 1 (23, 29). 
One of the most common causes is glucocorticoid therapy (Cortisol). Glucocorticoids affect 
bone by; stimulating osteoclast differentiation by increasing the expression of RANKL, 
decreasing osteoblast activity and inducing apoptosis of osteocytes (23, 29, 30). 
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Inflammatory diseases increase bone resorption by a direct effect on osteoclast activity trough 
inflammatory cytokines. In addition, many inflammatory diseases are treated with 
glucocorticoids. Malabsorption diseases such as celiac disease may reduce the intestinal 
absorption of calcium, inducing PTH secretion with subsequent increased bone resorption. 
Liver and kidney disorders can affect the hydroxylation and activation of vitamin D, which 
reduces the availability of biological active vitamin D. Vitamin D deficiency may also be 
caused by insufficient exposure to sunlight (23, 26, 27, 31). 
Primary hyperparathyroidism (PHPT) is a common endocrine disorder, characterized by an 
excessive production of parathyroid hormone (PTH) in combination with hypercalcemia. The 
increased levels of PTH are most commonly caused by a single parathyroid gland adenoma 
and rarely by parathyroid gland carcinoma (32, 33). Occurrence of PHPT increases with age 
and the incidence among postmenopausal women have been reported to range between 1.34 
and 3.4% in Scandinavian countries (34-36).   
The increased levels of PTH result in hypercalcemia through increased bone resorption 
combined with increased intestinal absorption and kidney reabsorption of calcium. Severe 
adverse effects of PHPT include osteoporosis, increased fracture risk, renal stones, peptic 
ulcers, constipation, neuropsychological and neuromuscular symptoms such as muscle 
weakness. However, in most cases, the condition is asymptomatic (around 80%) (32, 33). 
 Table 1. Secondary causes of osteoporosis            
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Nevertheless, progression into symptomatic disease may occur. There seems to be an 
association between decreased aBMD and increased fracture risk even in mild asymptomatic 
disease (37-40).  
Normocalcemic PHPT is biochemically characterized by calcium levels in the upper 
reference range combined with increased levels of PTH, in the absence of secondary causes. 
Normocalcemic PHPT has been associated with decrements of aBMD and the condition has 
been suggested to progress over time (32, 38). 
Surgical removal of the parathyroid glands (parathyroidectomy) has been proven beneficial in 
terms of osteoporosis, fracture risk, incidence of renal stones and quality of life, even in mild 
cases of the disease (32, 33, 39, 41-43). Surveillance of patients seems favorable when the 
surgical indications are not met (38). 
2.4.5 Osteoporosis-related fractures 
The clinical impact of osteoporosis is fractures and the most common fractures related to 
osteoporosis are: vertebral fractures, distal forearm fractures and hip fractures. In addition, 
fractures of the proximal humerus and pelvis may be regarded as osteoporosis-related. 
Osteoporosis-related fractures are the result of a low-energy trauma, commonly defined as 
falling from a standing height or a height less than 1 meter. Vertebral fractures, however, may 
occur without trauma (44).  
Distal forearm fractures are more common in women and the incidence rises abruptly in 
adjunction to menopause, with a plateau around the age of 65. On the contrary, vertebral 
fracture incidence begins to rise after menopause, around the age of 55, and continues to 
increase gradually. The hip fracture incidence increases exponentially with increasing age, 
but the rise begins at higher age compared to forearm and vertebral fractures. In men, the 
fracture risk generally increases 5-10 years later, compared to women (45, 46).  
Distal forearm fractures (Figure 6) cause acute pain and suffering. Many are at need of 
hospital care where the fracture in most cases is treated with a stabilizing cast or surgery, 
depending on fracture pattern, individual needs and preferences. A healed forearm fracture 
may be associated with joint stiffness, pain and functional impairment.  
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Vertebral fractures (Figure 7) can entail back pain, length reduction, deformity with increased 
kyphosis and protruding abdomen, reduced pulmonary function, reduced quality of life and 
increased mortality. Although many vertebral fractures occur without clinical verification (i.e. 
are incident radiographic findings), the clinical consequences seem to be similar (47, 48). 
 
                
 
A hip fracture (Figure 8) is an acute condition and the patient needs hospital care and surgery. 
Mortality following a hip fracture is around 25% within the first year from fracture after 
which it gradually decreases. Around 50% of those surviving a hip fracture suffer from life-
long functional impairment (44).  
 
Figure 6. Distal forearm fracture            
 
Figure 7. Vertebral fractures 
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Besides high individual morbidity and mortality, osteoporosis-related fractures have 
extensive consequences on society at large in terms of caregiving and costs (49, 50).    
2.4.6 Treatment 
Clinical considerations regarding the treatment of osteoporosis include addressing secondary 
causes and estimating the future fracture risk, which is determined by aBMD as well as other 
risk factors for fracture (Chapter 2.5). Non-pharmaceutical interventions, such as securing 
adequate nutritional status and reducing the risk of falls seem beneficial, although definite 
associations with fracture risk remains unclear. Pharmaceutical interventions are focused on 
reducing the bone loss and several approaches have been proven efficient in terms of 
reducing fracture risk. Pharmaceutical intervention predominately reduces the risk of 
vertebral fractures in postmenopausal women with osteoporosis. However, effects have also 
been seen on the risk of other osteoporosis-related fractures in women with a previous 
vertebral fracture. Vitamin D and calcium substitution is recommended as a compliment to 
the pharmaceutical intervention (18, 51, 52).  
Selective estrogen-receptor modulators (SERM) reduce bone loss by an estrogen agonist 
effect on bone. In addition, SERM reduce the risk of breast cancer by estrogen antagonist 
effects on breast tissue. Adverse drug effects include increased risk of deep venous 
thromboembolism (18, 51, 52).  
Bisphosphonates are analogues of pyrophosphate, which binds to hydroxyapatite. They cause 
osteoclast apoptosis by various mechanisms in the osteoclast after endocytosis, thereby 
reducing bone resorption. Bisphosphonates can be administered per os or intravenously. Rare 
Figure 8. Hip fracture             
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but severe adverse drug effects include osteonecrosis of the jaw (ONJ) and atypical femoral 
fractures (AFF) (18, 51, 52).  
Denosumab is an antibody, which binds to RANKL and thereby inhibits RANKL from 
binding to the RANK receptor on osteoclasts. The resulting decrement of osteoclast activity 
reduces bone resorption. Denosumab is administered by subcutaneous injection every 6 
months. Events of ONJ and AFF have been reported but the associations remain unclear (18, 
51, 52).  
Teriparatide is an artificially produced parathyroid hormone, which when given 
intermittently, increases bone formation by affecting osteoblasts. Teriparatide is administered 
by daily subcutaneous injections during 18 months. Treatment is contraindicated if the patient 
has suffered from malignancy or if concurrent metabolic bone disease or severe renal disease 
is present (18, 51, 52).   
2.5 RISK FACTORS FOR FRACTURE 
In Sweden, around 20% of all women over the age of 50 have osteoporosis, compared to 7% 
in men. In total, around 50 000 osteoporosis-related fractures (distal forearm, hip, vertebral) 
are reported every year (53). Many of these fractures could have been prevented with 
adequate treatment interventions that lowers fracture risk (18, 51, 52).  
The clinical challenges lie in knowing whom to treat. Low aBMD is a strong predictor for 
subsequent fracture (54-56), and the fracture predictive ability of aBMD has been proposed to 
be equivalent to that of high blood pressure and the risk of stroke (54). However, many 
osteoporosis-related fractures occur in women without osteoporosis defined by aBMD (T-
score ≤ -2,5) (55, 57). Furthermore, aBMD have demonstrated decreasing fracture 
predictability with age (56).  
This suggests that other factors influence fracture risk, especially in the elderly. 
Consequently, several clinical risk factors have been identified. Table 2 illustrates the most 
common risk factors associated with fracture independent of aBMD (57-59). 
The clinical risk factors have varied significance and are evaluated together with aBMD in 
determining the individual fracture risk. Consideration of all risk factors is of importance in 
targeting treatment of patients at highest risk. Integrating algorithms such as FRAX (Fracture 
risk assessment tool), have therefore greatly improved the clinical evaluation. 
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FRAX was developed by the WHO and provides a standardized estimation of the fracture 
risk based on a combination of validated clinical risk factors, with or without aBMD (60). 
The result is a 10-year probability of hip fracture or osteoporosis-related fracture. The 
probabilities are gender and country specific, and the clinical risk factors included in FRAX 
are the same as depicted in table 2, apart from falls. Although favorable in a clinical setting, 
there are limitations with FRAX. The gradient of risk that some of the dose dependent risk 
factors entails, such as the amount of glucocorticoid, alcohol and tobacco use, is not 
considered. Measures of bone mass other than aBMD, such as volumetric BMD, are not 
included. Moreover, the risk of falling and indices physical function is not considered (59, 
61). 
FRAX is widely used as a diagnostic supplement and is recommended by the International 
Society for Clinical Densitometry (ISCD) and the International Osteoporosis Foundation 
(IOF) (62). In Sweden, the Swedish National Board of Health and Welfare includes FRAX in 
the national guideline regarding assessment of fracture risk (63).  
2.6 MEASUREMENTS OF BONE MASS AND STRUCTURE 
2.6.1 Dual-energy X-ray absorptiometry 
The most validated and widely used method to estimate bone mass is by Dual-energy X-ray 
absorptiometry (DXA), which measures areal bone mineral density (aBMD).  
The principle for DXA in measuring bone mass is quantifying the attenuation, i.e. the 
reduction of photons from an x-ray beam after passing through the body. The attenuation is 
determined by the density and the thickness of the tissue, higher density causes higher 
attenuation. By using x-ray beams with two photon energy peaks, it is possible to separate 
 Table 2. Independent risk factors for fracture             
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bone from soft tissue. The result is bone mineral content (BMC) in grams, which divided by 
the bone area gives an estimation of the two-dimensional areal bone mineral density (aBMD) 
in g/cm2. The effective radiation dose varies depending on the region studied, gender, DXA 
devise and model. In general, the effective dose of a spine DXA ranges between 13-15 µSv 
(64-66).   
 
 
 
DXA devices require an x-ray generator, a collimator (beam limiting device), a detector, 
software and a phantom for calibration. Differences in DXA device composition influence 
the comparability of aBMD derived from different units (64).  
Peripheral DXA refers to measurements of the extremities while central DXA refers to 
measurements of the lumbar spine and hip. Central DXA has been extensively studied with 
large reference populations, has a relatively high precision and is considered gold standard in 
clinical settings. Central aBMD derived from central DXA is a strong predictor of fracture 
and a suitable variable for monitoring treatment or progression. The effective radiation dose 
is relatively low. By comparison, the natural background radiation is around 6,6 µSv/day (54, 
65, 67, 68).   
A limitation with DXA lies within the two-dimensional estimation of aBMD; DXA does not 
indicate the true volumetric BMD. Areal BMD derived from DXA is reported as areal BMD 
(denoted aBMD) when compared to true volumetric BMD in mg/cm3 (denoted BMD) 
derived from devices capable of three-dimensional estimations (2.6.2). Factors that can 
impair aBMD estimations include degenerative changes in the hip and spine, fractures and 
implant devises in bone or other tissues, and calcifications in other tissues such as kidney 
stones and atherosclerosis (69, 70).   
Figure 9. Dual-energy X-ray absorptiometry (DXA)             
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2.6.2 Peripheral quantitative computed tomography 
Peripheral quantitative computed tomography (pQCT) is a site-specific volumetric method to 
evaluate bone mass, which allows for a separate evaluation of cortical and trabecular bone. 
 
 
 
Peripheral quantitative computed tomography is a CT based photon absorptiometry method. 
In CT images, the amount of attenuation varies depending on the constituents of the tissue. 
The variation is expressed in Hounsfield Units (HU), which quantifies the constituents by 
relating to the attenuation of water. The conversion of HU to bone parameters requires 
calibration with a specific phantom (71, 72). Central QCT refers to measurements of the 
spine and hip, while peripheral QCT (pQCT) refers to measurements of the radial bone (distal 
forearm) or tibia (lower leg). As with DXA, the effective radiation dose depends on several 
variables. Measured effective doses in spine QCT range between 200-1000 µSv, with 
considerable lower doses in pQCT (<10 µSv) (71, 72). 
QCT measures true volumetric BMD in mg/cm3 and thus provides a more accurate estimation 
of bone constitution compared to DXA. PQCT distinguishes trabecular bone from cortical 
bone, which allows for separate analysis of these bone compartments in terms of BMC and 
BMD. In addition, structural and geometric variables, such as cortical thickness, area and 
circumference, may be assessed. Furthermore, pQCT has the ability of determining muscle 
density and area. (71-73).  
During a forearm pQCT scan the length of the forearm is initially determined, followed by a 
coronal scout and the positioning of a reference line, which marks the ulnar side of the radial 
bone articular surface. Scans are then performed, usually at the distal (4% of the radial bone 
length) and proximal (60-66% of the radial bone length) parts of the radial bone. These 
scanning sites are preferred as the distal part of the bone is rich in trabecular bone and the 
proximal part mainly consists of cortical bone (71, 72). 
Figure 10. Peripheral quantitative computed tomography (pQCT)       
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Forearm pQCT measures has been shown to correlate with subsequent hip and forearm 
fracture, but not vertebral fracture. On the contrary, spine QCT measures has been shown to 
correlate with vertebral fracture, but not hip and forearm fracture. However, compared to 
DXA, QCT measurements are not as widely used and consequently not similarly validated. 
Few large reference populations are available and differences in scanning procedures, 
scanning regions, software applications and presented variables impede comparisons between 
studies. Bone variables from pQCT cannot be applied to the WHO diagnostic classification of 
osteoporosis, but may be used in monitoring disease and treatment. For these reasons, pQCT 
is mostly used in research settings and is not widely used among clinicians  (25, 71, 72). 
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3 AIMS OF THE THESIS 
The main purpose with this thesis was to identify and further specify factors important in the 
fracture risk assessment. A deeper understanding of the risk factors for fracture could 
improve the identification of women at risk.  
I.  To determine whether women in a study on osteoporosis and risk factors for fracture 
are representative also for the women that declined participation.  
II.  To determine whether objective and subjective indices of physical function have a 
fracture predictive ability in elderly women at different ages.  
III. To determine whether smoking and smoking cessation affect fracture risk in elderly 
women.   
IV. To determine whether site-specific musculoskeletal changes in terms of geometry and 
mass are apparent in women with a distal forearm fracture, and to determine whether 
PTH and vitamin D affect muscle and bone properties.  
V.  To determine the prevalence of primary hyperparathyroidism (classical and 
normocalcemic) in women with a distal forearm fracture.  
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4 RESEARCH APPROACH 
4.1 STUDY POPULATIONS 
The studies in this thesis were based on two different populations of elderly women, the 
OPRA cohort and the DFF cohort.  
4.1.1 The OPRA cohort 
The Osteoporosis Prospective Risk Assessment study (OPRA) was initiated to study risk 
factors for fractures and osteoporosis in elderly women. The OPRA study is an ongoing 
population-based study and the cohort consists of elderly women that were recruited at 
random by the means of population files between the years 1995-1999. During recruitment, 
women in the city of Malmö, Sweden, received a letter of invitation 1 week after their 75th 
birthday. In case of no response, reminders were sent by letter or made by telephone. In total, 
1604 women were invited. Of the women invited, 1044 accepted participation and were 
included in the cohort (participants), and 560 women did not participate (non-participants). 
Out of the 560 non-participants, 376 women were unwilling to partake and 139 women 
declined because of illness. The remining non-participants were not reached (74).     
At baseline, women in the cohort underwent extensive examinations, including blood 
sampling and DXA. Tests of physical function were performed and the women answered a 
questionnaire. The procedure was repeated at the 5-year follow-up and at the 10-year follow-
up. At the age of 85, the women in addition underwent a pQCT examination of the forearm.   
4.1.2 The DFF cohort 
The Distal Forearm Fracture study (DFF) was initiated at Karolinska University Hospital, 
Stockholm, Sweden. Postmenopausal women who sought the emergency ward with a distal 
forearm fracture between April 2010 and January 2015 were invited to participate. Criteria 
for participation included fracture due to low-energy trauma and that they were past 
menopause. No exclusion criteria were applied. The study procedure involved a blood sample 
at the emergency ward and an invitation to the research facility where they answered a 
questionnaire and left a supplementary blood sample and, if needed, underwent further 
examinations. After recruitment of all patients to Paper IV, patients were recruited only to 
Paper V (Figure 11).  
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To the study group in Paper IV, 127 women accepted participation at the emergency ward. 
Out of these, 7 women were excluded because of unwillingness. The women were examined 
with DXA and pQCT in addition to the previously mentioned screening procedure (blood 
screening, questionnaire, supplementary sample). Subsequently, 16 women were withdrawn 
from analysis because pQCT measurements were conducted on a previously fractured arm 
(n=13) or missing data (n=3). In total, 104 women with a mean age of 64 were included. 
Age-matched controls were recruited from the population register. Letters of invitation were 
sent to 362 women with one reminder if needed. Controls with a known bone remodeling 
disease, history of an osteoporosis-related fracture, antiresorptive-, estrogen- or oral 
glucocorticoid treatment were excluded. In all other regards, the examination protocol was 
identical in cases and controls. In total, 99 controls with a mean age of 65 were included. The 
total mean age (both cases and controls) in Paper IV was 65 years. 
To the study group in Paper V, another 41 patients were recruited to evaluate the PHPT 
prevalence. In total, 161 women were included in Paper V, all of whom underwent a 
procedure with blood screening, questionnaire and supplementary sample followed by a 
complete biochemical and physical examination at the department of Endocrinology. 
Repeated evaluations were performed if needed.  
 
 
Figure 11. The recruitment process in Paper IV and V      
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4.2 DATA COLLECTION 
4.2.1 Mortality 
Mortality was registered in the OPRA cohort by cross-referencing the 10-digit personal 
identification number against the population registry. Mortality data were registered for all 
women in the OPRA cohort, participants as well as non-participants.  
4.2.2 Fractures 
Fractures in the OPRA cohort were continuously registered by collecting radiology files from 
the Department of Radiology at Skåne University Hospital using the personal identification 
number. The radiological files from the hospital can be regarded as near complete, with less 
than 3% loss (75). In case of uncertainties in the radiology files, the radiology images were 
reviewed. This was the sole means of fracture registration in Paper I; to avoid discrepancies 
between participants and non-participants. In Papers II-IV, fracture registration through 
radiology files was complemented with questionnaire information.  
4.2.3 Questionnaire 
Participants in the OPRA study and DFF study answered an identical comprehensive 
questionnaire regarding diet, lifestyle, smoking, physical activity, history of falls, fracture, 
disease, medication and heredity. Information on smoking habits included: current or former 
smoker, time as smoker and amount smoked.  
4.2.4 Physical performance tests 
Gait speed, balance test and knee extension force were performed by the OPRA study 
participants at baseline (age 75) and at follow-up (age 80). Three attempts of each test were 
made and the best was registered. One of three physiotherapists supervised and the approach 
was identical for all participants.  
Gait speed was evaluated by the time it took to walk 15 meters back and forth and the women 
were urged to walk as fast as they could. The balance test was evaluated by the ability to 
stand on either the left or right leg with eyes open. The test proceeded for 30 seconds. 
Managing to stand on one leg for more than 5 seconds was considered a passed test. Knee 
extension force was measured as isometric muscle strength with the knee in 90 degrees of 
flexion in a dynamometer (Biodex Medical Systems, Version 4.5.0, Biodex Corporation, 
Shirley, N.Y., USA). Participants in the DFF study did not perform physical performance 
tests. 
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4.2.5 Parathyroid hormone and Vitamin D 
In Paper IV, PTH and 25-hydroxy vitamin D (25OHD) were analyzed from frozen serum 
samples by the same laboratory and methodology at Skåne university hospital in Lund (both 
OPRA and DFF cohort). In Paper V, PTH and 25OHD were analyzed at the Karolinska 
University Hospital. Serum calcium was corrected for albumin by the formula: Calcium + 
0.01 x (39-albumin).  
4.2.6 Peripheral Quantitative Computed Tomography 
Structural and material properties of the forearm were assessed by peripheral Quantitative 
Computed Tomography (pQCT). Bone variables assessed were: BMD, BMC, cross-sectional 
area (CSA), cortical thickness, endosteal and periosteal circumference. Bone strength was 
assessed by strength strain index (SSI) and bone strength index (BSIc), defined as; total 
BMD2 * CSA at the distal 4% site (76). 
Stratec XTC-2000 (Stratec Medizintechnik, Pforzheim, Germany) with software version 6.2 
provided by the manufacturer was used in both cohorts (OPRA and DFF). The European 
Forearm Phantom (EFP) was used for calibrations in both cohorts and calibrations were 
performed for each subject. CV% for the forearm phantom was 0.27. The EFP was tested in 
both devices by the manufacturer with a Pearson correlation coefficient of 1.00. 
Measurements included distal radius and radius shaft (4% and 66% of ulnar length proximal 
to the reference line). Voxel size was 0.5 mm, slice thickness 2.3 mm and scanning speed 20 
mm/s. To separate bone from soft tissue, a 180 mg/cm3 density threshold was applied at the 
4% site and a 280 mg/cm3 threshold at the 66% site. Trabecular bone was evaluated at the 4% 
site and cortical bone at the 66% (72). 45% of the area at the distal (4%) site was determined 
as trabecular bone. An inner threshold of 711 mg/cm3 differentiated cortical bone at the shaft 
(66%) site. A density threshold of 40 mg/cm3 distinguished muscle tissue at the 66% site.  
4.2.7 Dual energy X-ray Absorptiometry 
Areal bone mineral density was determined by Dual energy X-ray Absorptiometry (DXA). In 
the DFF cohort, measurements included lumbar spine, femoral neck, ultra-distal radius 
(UDR) and 33% of radius length. In the OPRA cohort, measurements included lumbar spine, 
femoral neck and arm. In the lumbar spine, measurements of the first and second lumbar 
vertebrae (L1-L2) were chosen to minimize artifacts by degenerative changes (77). The left 
femoral neck was used for analysis. Calibrations were made with a spine phantom three times 
every week and automatic calibrations were made daily.   
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In the DFF cohort, measurements were performed with GE Lunar iDXA (GE Medical 
systems, Chalfont St. Giles, UK). A correlation coefficient (CV) of 1,5% was determined for 
the phantom. In the OPRA study, measurements were performed with Lunar DPX-L (Lunar 
Corporation, Madison, Wi, USA). CV was 1,4% for the phantom.  
4.2.8 Site-specific measurements by pQCT and DXA 
In the DFF cohort, measurements were performed at the non-fractured forearm with a 
matching number of sides in the controls. There was no difference between cases and 
controls regarding right- or left-handedness. The left arm was examined in the OPRA cohort 
except in three cases. Women with a previous fracture at the examined arm, missing or 
otherwise invalid measurements were excluded in the analysis. 
4.3 STUDY OUTLINE 
4.3.1 Paper I 
Mortality and fracture rates in the 1044 participants and 560 non-participants in the OPRA 
study were compared.  
Mortality was compared with Kaplan-Meier curves and log-rank test. Fracture incidence was 
compared with the Mann-Whitney U-test. Cumulative fracture incidence with consideration 
of competing risks was compared with Grey´s test.  
4.3.2 Paper II 
The fracture predictive ability of physical function tests (gait speed, standing balance, knee 
extension force and self-reported history of falls) was evaluated in the 1044 women 
participating in the OPRA study. Participants were examined at inclusion with repeated 
examinations after 5 years at the age of 80. The fracture predictive ability of each test during 
10 years of follow-up was determined. In addition, the fracture predictive ability at the age of 
75 was compared to the fracture predictive ability at the age of 80.  
Standing balance and history of falls were dichotomized. Univariate and multivariate hazard 
ratios with 95% CI, adjusted for known risk factors for fracture, were determined with 
univariate and multivariate Cox proportional hazards regression (with BMD, BMI, previous 
fracture, smoking, alcohol-, vitamin D-, glucocorticoid- and bisphosphonate use as 
covariates).   
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4.3.3 Paper III 
Fracture rates in non-smokers, current smokers and former smokers during 10 years of 
follow-up in the OPRA study were determined. The fracture rate in current (n=145) and 
former smokers (n=209) was compared to the rate in non-smokers (n=679). Time as a 
smoker, amount smoked and time from cessation were analyzed in relation to fracture risk.   
Univariate and multivariate cumulative fracture incidence with consideration of competing 
risks was estimated with univariate and multivariate proportional hazards regression.   
4.3.4 Paper IV 
Site-specific volumetric material and structural properties of bone and muscle in the forearm 
was determined by pQCT. Measurements were performed in the DFF cohort (mean age 65) 
and in a subset of the OPRA cohort (mean age 85). Women with a distal forearm fracture 
were compared to age-matched controls without fracture within each cohort. Furthermore, the 
correlation of PTH and 25OHD with volumetric bone and muscle variables was assessed.  
Comparisons between cases and controls were made with independent t-tests and analysis of 
covariance (ANCOVA). In a separate ANCOVA, volumetric pQCT variables were adjusted 
for site-specific aBMD by DXA. Correlations of PTH and vitamin D with bone and muscle 
variables were assessed for all women (regardless of fracture status), with multiple linear 
regression. 
4.3.5 Paper V 
The prevalence of PHPT was determined by clinical and biochemical examination of 161 
women participating in the DFF study. PHPT diagnosis was based on repeated evaluations of 
PTH and calcium levels in the absence of secondary causes. The biochemical definition of 
PHPT was based on combinations of PTH and calcium levels, designed with a similar 
approach as has been reported previously in population prevalence reports. PHPT was 
subdivided into “classical PHPT” and “normocalcemic PHPT”. Elevated PTH ( > 65 ng/L) in 
combination with elevated serum calcium ( > 2.50 mmol/L) was considered classical PHPT. 
Elevated PTH ( > 65ng/L) in combination with serum calcium within, but in the upper part of 
the reference interval (2.15-2.50 mmol/L), was considered normocalcemic PHPT.  
Comparison of PHPT prevalence with population prevalence was made with a binominal 
two-tailed exact test.   
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4.4 STATISTICAL CONSIDERATIONS AND POWER 
No calculation of power was performed before analysis in Paper I-III, since the sample size 
was deemed sufficient for the planned analyses.   
In Paper IV the following assumption was made: To find a difference in bone density of 10%, 
i.e. 20 mg/cm3 at a standard deviation of 45 mg/cm3, 81 patients and 81 controls (α = 0.05 
and power 80%) would be needed. If the case-control ratio was 1:4, 53 cases and 159 controls 
would be needed.    
In Paper IV the following assumption was made: Previous population reports have indicated 
a population prevalence of PHPT around 2%. In our study group, we have previously found 
prevalence around 6% in postmenopausal women with a distal forearm fracture (78). 
Considering that the estimated prevalence in the study population is 0.06, it follows that 141 
patients are required to find a difference (α = 0.05 and power 80%).  
A p-value < 0.05 was considered as level of significance in all papers.    
4.5 ETHICAL APPROVAL  
All parts of the studies were performed with ethics committee approval and informed 
consent.  
 Paper I-II. Approved by the Ethics committee of Lund University (LU 200-95). 
Paper III. Approved by the Ethics committee of Lund University (LU 200/95). 
Paper IV. Approved by the Regional ethical boards in Stockholm and Lund, and the Ethics 
committee of Lund University (2009/913-31, 2014/804, LU 200-95). 
Paper V. Approved by the Regional ethical board in Stockholm (2009/913-31). 
4.5.1 Ethical considerations 
Increased identification of patients at risk could lead to preventive measures initiated at an 
earlier state, thus reducing fracture rates. A prerequisite for this is that there are effective and 
acceptable treatment options for osteoporosis available. Osteoporosis itself is a silent disease, 
but its consequence, fracture, is associated with increased mortality and mortality. In addition, 
the socioeconomic consequences are vast. Prevention of fractures could benefit not only the 
affected patient, but also society at large.  
Hyperparathyroidism is proposedly an underdiagnosed condition that, besides osteoporosis, 
can lead to vague symptoms like fatigue, muscle aches, constipation and kidney stones. 
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Presuming an increased prevalence of primary hyperparathyroidism in postmenopausal 
women with forearm fracture, as previously indicated (78, 79), the event of fracture might be 
an opportunity to identify undiagnosed individuals. This also assumes available and 
acceptable treatment options.  
All study participants and controls in the OPRA and DFF study received information of the 
planned investigations and risks and gave informed consent. Uncovered diseases and 
fractures were treated per clinical routines. Participants could at any time, without reason, 
choose to cancel and withdraw their participation. Records and data files were treated with 
confidentiality.  
A blood sample was taken which may cause discomfort and in rare occasions side effects 
such as local infections. Radiation doses with DXA and pQCT are generally low (equivalent 
to less than a standard chest x-ray).   
In Paper I, participants and non-participants were studied. We studied fracture rate and 
mortality through radiological files and population files solely. It involved no risk or 
inconvenience for the women and the data were not presented on an individual basis. 
Nevertheless, an ethical dilemma was recognized; informed consent from non-participants 
was not obtained. This would have been practically difficult since the study is based on 
comparing the very ones who declined participation. We considered these aspects and 
concluded that these women would not suffer from the "non-participation". From a utilitarian 
perspective, it would be beneficial to complete the study.  
5 RESULTS 
5.1 PAPER I  
Mortality was higher in non-participants; 372 out of 560 (66%), when compared to 454 out of 
1044 (44%) in participating women (Figure 12). Vertebral and distal forearm fracture 
incidence rates were lower in non-participants, when compared to participants (IR: 10 vs 13 
and 7 vs 11 respectively, p ≤ 0.007). Multiple fractures were less common among non-
participants (IR: 14 vs 20, p ≤ 0.001). Other specific fractures (proximal humerus, pelvis, hip) 
and fracture groups (osteoporosis-related, any) were without significant difference between 
non-participants and participants.   
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5.2 PAPER II 
A history of fall corresponded to an increased risk of distal forearm fracture (HR 1.60, CI 
1.03-2.48) any fracture (HR 1.30, CI 1.03-1.65) and any osteoporosis-related fracture (HR 
1.39, CI 1.08-1.79) in the 10-year follow-up after adjustment for possible confounding 
variables. Decreased gait speed (HR 1.37, CI 1.14-1.64) and a failed balance test (HR 1.98, 
CI 1.18-3.32) was associated with increased risk of hip fracture. Knee extension force was 
not associated with fracture risk in the 10-year follow-up.   
In the first 5-year follow-up from the age of 75, a history of fall, decreased gait speed and 
failed balance test corresponded to an increased risk of hip fracture. In addition, a history of 
multiple falls was associated with increased risk of any osteoporosis-related fracture, whereas 
decreased gait speed and knee extension force was associated with increased clinical 
vertebral fracture risk.   
In the second 5-year follow-up from the age of 80, a history of fall corresponded to increased 
risk of hip fracture, any fracture and any osteoporosis related fracture. Reduced gait speed 
was associated with increased risk of hip fracture.  
5.3 PAPER III 
When compared to non-smokers, current smokers had an increased risk of contracting any 
osteoporosis-related fracture (HR 1.47, CI 1.05-2.05) and vertebral fracture (HR 2.50 CI 
1.58-3.95) after adjustment for possible confounding variables. Former smokers had an 
Figure 12. Cumulative survival in participants and non-participants in the OPRA cohort (Paper I) 
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increased risk of contracting proximal humerus fracture (HR 2.07, CI 1.19-3.57). Increased 
risk for other fracture types were not observed in current and former smokers after adjustment 
for possible confounding variables.   
Time as a smoker was associated with increased risk of vertebral fracture (HR 2.66, CI 1.57-
4.53) and decreased risk of distal forearm fracture (HR 0.38, CI 0.17-0.86), whereas amount 
smoked did not affect fracture rates. Time from cessation did not affect fracture rate in former 
smokers.   
5.4 PAPER IV 
In the DFF cohort, women with a distal forearm fracture had decreased central aBMD, 
increased time spent walking/day and more frequently reported a history of falls, compared to 
controls. These variables did not differ in the OPRA cohort.  
Compared to controls, women with a distal forearm fracture in the DFF cohort had decreased 
forearm volumetric mean trabecular BMD (167.5 vs 125.1, p < 0.001), cortical BMD (1120.8 
vs 1095.7, p= 0.007), total BMC at the 66% site (89.8 vs 81.4, p < 0.001) and BSIc (30.8 vs 
22.1, p < 0.001) after adjustments for possible confounding variables. In addition, mean CSA 
(319.8 vs 336.4, p= 0.033) and endosteal circumference (27.8 vs 30.1, p < 0.009) was greater 
while cortical thickness was lower (1.996 vs 1.726, p < 0.001) in women with fracture. 
Periosteal circumference, Strength strain index and muscle parameters did not differ. 
After additional adjustment for site specific aBMD by DXA, a difference in trabecular BMD, 
total BMC at the 66% site and cortical thickness remained.  
In the OPRA cohort, differences in volumetric trabecular BMD, total BMC at the 66% site 
and BSIc was similar to those found in the DFF cohort. No difference in structural 
(geometric) parameters were observed in the OPRA cohort, between women with fracture 
and controls. 
Mean PTH and 25OHD did not differ between women with and without a forearm fracture. 
In the DFF cohort, weak negative correlations were observed between PTH and site specific 
volumetric trabecular and cortical BMD as well as aBMD of the femoral neck. Weak positive 
correlations were observed between 25OHD and site specific volumetric trabecular BMD and 
aBMD of the lumbar spine. Significant correlations were absent in the OPRA cohort, except 
for a weak positive correlation between PTH and aBMD of the femoral neck.  
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5.5 PAPER V 
Of the 161 women with a distal forearm fracture, 13 women (8%) were diagnosed with 
PHPT. Classical PHPT were observed in 7 women and normocalcemic PHPT in 6 women. In 
total, 6 women presented with symptomatic disease (3 with classical PHPT and 3 with 
normocalcemic PHPT). Osteoporosis (T-score < -2.5) were observed in 3 women. The 
observed PHPT prevalence in the 161 women with a distal forearm fracture was significantly 
greater than a population prevalence of 3.4% (p=0.004).  
In addition, 32 women (20%) presented elevations of PTH for reasons other than PHPT.   
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6 DISCUSSION 
 
External validity  
When identifying risk factors in epidemiological research, it is important that the results are 
generalizable. In population based studies, external validity can be assessed by comparing the 
characteristics of participating individuals with non-participants, i.e. individuals that decline 
participation or for other reasons are unable to participate. If the non-participants differ 
substantially from the participants, the external validity is reduced which might induce non-
response bias into the study. Thus, the external validity is not solely dependent on a high 
response rate. Knowledge of the non-participating individuals is essential when interpreting 
and correcting for non-response bias (80, 81). Most studies are dependent on voluntary, 
active participation and for understandable reasons prospective information on the 
characteristics of non-participants is poorly described. 
The finding of increased mortality among non-participating women in the OPRA cohort is in 
line with findings from the EVOS study on vertebral fractures (82), as well as studies from 
other disease areas (81, 83-90). Indicating a poorer health status in non-participating women 
compared to participating women.   
However, this did not seem to entail increased fracture rates in non-participants. On the 
contrary, multiple fractures, distal forearm fractures and vertebral fractures were slightly 
more frequent in participating women. Analysis of fracture incidence in participants and non-
participants prior to inclusion have suggested that studies on osteoporosis and fracture might 
attract individuals prone to fractures (82, 91, 92), which in part might explain the seemingly 
increased fracture rates. A longer life-span and thus a longer time at risk for fracture might 
also contribute to some of the observed differences. 
The rate of hip fracture and proximal humerus fracture did not differ between groups 
although an increased hip fracture rate among non-participants has been suggested previously 
(93). The finding of increased clinical vertebral fracture rate was somewhat in line with a 
previous study in which participants more frequently reported back pain, although, 
radiographic imaging were not used (92). Compared to others, our study had the advantage of 
being able to follow a large population for a long period. In terms of mortality and fracture 
rates, the OPRA cohort can be regarded as almost complete.  
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Physical performance tests and history of falls as clinical risk factors for fracture  
In a clinical setting, establishing the future fracture risk is essential in determining the level of 
preventive interventions. It has been suggested that an impaired postural stability may be 
associated with an increased fracture risk, but measures of postural stability are not included 
in the most widely used tool for fracture risk assessment, FRAX. Postural stability can be 
evaluated by the occurrence of previous falls or through physical performance tests, e.g. 
balance, gait speed and lower extremity muscle strength. 
The most commonly described measure of postural stability, self-reported history of falls, has 
been associated with increased risk of any fracture (94-98), hip fracture (99-101), distal 
forearm fracture (102-104) and proximal humerus fracture (105), although not all concur 
(102, 103, 106). Reduced gait speed have predominately been associated with increased risk 
of hip fracture (99, 107, 108) and a failed standing balance tests with any fracture (109), 
proximal humerus fracture (102, 105) and hip fracture (108), while decreased lower extremity 
muscle strength have shown some predictive value in terms of any fracture (109) and hip 
fracture (100). However, long-term prospective data is sparse and several studies have failed 
to demonstrate associations (95, 102, 103, 106, 107). The fracture predictive ability of these 
measures remains unclear.    
A self-reported history of fall was during 10-years of follow up in the OPRA cohort 
associated with an increased risk of osteoporosis-related fracture, any fracture and distal 
forearm fracture. In general, history of multiple falls was associated with greater risks of 
fracture. However, we were not able to reproduce hip and proximal humerus fracture 
predictability as previously suggested (99-101, 105).  
Reduced gait speed was a strong predictor for future hip fracture in our study. Associations 
were also observed with several other fracture types in the univariate analysis, but these 
associations were lost after adjustments for aBMD and other possible confounders.    
A failed balance test at the age of 75 doubled the hip fracture risk which in the OPRA cohort 
was comparable to the fracture predictability of a standard deviation decrease in femoral neck 
aBMD. This finding was in line with other studies examining balance by postural sway (100) 
and tandem walk (107). Although not all concur (106), our findings have since been 
strengthened by the results by Lundin et al who demonstrated increased hip fracture risk with 
failing a one-leg standing balance test (108). A failed balance test did not increase the risk of 
other fractures in the OPRA cohort, even though this has been previously proposed (102, 105, 
109).  
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Knee extension weakness did not seem to increase fracture risk after adjustments for femoral 
neck aBMD. However, some associations were seen in the univariate analysis, suggesting 
that some of the fracture predictability of knee extensor strength might be related to aBMD.   
The balance test seemed to lose predictability with age as it was predictive of hip fracture at 
the age of 75, but not at the age of 80. On the other hand, gait speed and self-reported history 
of at least one fall were predictive of hip fractures in both 75-year old and 80-year old 
women.  
These tests that evaluate the physical function are easy to implement and require no complex 
equipment, which are considerable benefits in a clinical environment.    
Smoking, smoking cessation and fracture risk  
Smoking has previously been associated with increased fracture risk and the dose as well as 
duration of exposure seem to affect the risk (110-112). However, reports showing a lack of 
association with hip fractures (99, 113, 114) and any osteoporosis-related fractures (115) 
have been presented in smokers. It has been indicated that the effect of smoking on bone 
mass and fracture risk is reversible (110, 112, 115), but a lack of reversible effect in terms of 
hip fractures have been shown (116).  
Smokers in the OPRA cohort had an increased risk of fracture, and the risk of vertebral 
fracture was particularly increased. A biological effect of smoking on bone remodeling has 
been proposed (117), in line with our findings, suggesting a greater effect of smoking on 
trabecular bone with a higher remodeling rate, compared to cortical bone. Former smokers 
also had an increased risk of fracture, but not for vertebral fracture, suggesting reversible 
effects of smoking cessation primarily on skeletal sites comprised of trabecular bone. 
The hip fracture risk was not increased in smokers in the OPRA cohort, although an 
association have been reported by several authors (112, 118, 119). Furthermore, a previous 
report on the OPRA cohort have shown decreased hip aBMD in smokers, which ought to 
increase the susceptibility for fracture (74). However, in a recent meta-analysis, associations 
between smoking and hip fracture risk were not found in most studies with elderly 
participants (112). The effect of smoking on hip fracture risk may be dependent on age; in 
younger populations, smoking seemed to increase hip fracture risk (112, 115). It is plausible 
that other risk factors for hip fracture are more prominent than smoking and aBMD in the 
elderly. 
Smoking cessation did not affect the risk of any fracture which has previously been proposed 
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(112, 119). The effects of smoking on the risk of any and any osteoporosis-related fracture 
seemed to last for a long time, further emphasized by the lack of risk reduction with time 
from cessation. In addition, it appeared as if the risk of fracture was independent of the 
amount smoked. 
Site-specific structural and material properties in elderly women with forearm fracture  
Distal forearm fractures most often occur in younger postmenopausal women and the event 
of a distal forearm fracture may be the first sign of osteoporosis. Bone strength is dependent 
on the structural properties (geometric) and the material properties (mineralization and 
density) of the bone as well as the proportion of cortical and trabecular bone. Evaluation of 
these properties are important in understanding the pathogenesis of fracture. 
Decrement of aBMD by DXA of the hip and forearm have shown an association with 
increased forearm fracture risk (54, 103, 120-122), but aBMD only partially evaluate aspects 
of bone strength (72). Using pQCT, geometric and material changes of the forearm have been 
proposed as causative factors in mechanical in vitro studies (72, 123, 124). However, clinical 
associations are sparse and with either a small sample size (121, 125-128) or retrospective 
approach (120, 129).  
Findings in the DFF study suggests that both forearm trabecular and cortical bone decrements 
are present in postmenopausal women with a distal forearm fracture, even though the 
trabecular reductions seemed to be more prominent. Although not all concur (127), these 
findings are in line with previous reports (120, 121, 125, 126, 129).  
Geometric changes were also observed. Women with fracture had decreased cortical 
thickness and increased endosteal circumference as well as cross sectional area. While a 
thinner cortex with increased diameter has been associated with ageing (72, 130-132), 
increasing size has not been demonstrated in previous studies in women with fracture (120, 
121, 125-128). In normal ageing, it has been proposed that the cross-sectional area increases 
as a response to decrements of bone mass, providing a favorable structure in terms of bone 
strength (72, 130-132). The increased area in women with fracture might thus be an effect of 
the lower bone mass. However, these geometric alterations appeared insufficient in terms of 
maintaining bone strength in the women with a forearm fracture. Strength index, which 
accounts for both bone mass and geometry, has previously been associated with decreased 
bone resilience (130). However, the stress-strain index in our study was surprisingly not 
changed.  
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Site-specific aBMD by DXA was also lower among women with fracture and when adjusted 
for aBMD, some of the volumetric parameters lost significance. However, changes in 
volumetric trabecular BMD as well as cortical BMC and thickness persisted, indicating that 
volumetric changes not visualized by DXA were present.  
Women with a forearm fracture in the DFF cohort had on average a higher activity level and 
more frequently reported a history of fall. Central aBMD of the femoral neck and aBMD of 
the lumbar spine were, in addition, lower among women with fracture compared to controls. 
These differences were not seen in a subset of women at the age of 85 in the OPRA cohort. In 
the OPRA cohort, volumetric changes were less apparent, apart from trabecular BMD. This 
suggests that other factors are of importance in the pathogenesis of forearm fracture in the 
elderly.       
Parathyroid hormone disturbances in postmenopausal women with forearm fracture 
Increased levels of PTH have been associated with decreased BMD in women with 
parathyroid disease and the reductions seems to be a result of both cortical and trabecular 
bone loss (133-137). In Paper IV, neither PTH nor 25OHD were associated with forearm 
fracture risk, but weak correlations of PTH and 25OHD with volumetric and areal BMD were 
observed.  
Women with PHPT have been shown to be at risk of fracture (33, 40) and conversely, there 
have been suggestions of increased PHPT prevalence among women with fracture (78, 79). 
The high prevalence of PHPT in Paper V are in line with previous findings in women with a 
distal forearm fracture (78, 79), and other fractures (138-141). However, a lack of association 
has also been presented (142). Differences in study design and biochemical definition of 
PHPT complicates comparisons between studies and population prevalence. Nevertheless, by 
thoroughly examining 161 women with a distal forearm fracture we observed a substantial 
number of women with PHPT and other parathyroid hormone disturbances. Even though 
many of the women with PHPT in this study were mild cases, identifying these would be of 
value as the disease may progress and surveillance seems beneficial (32, 38, 143). 
6.1 LIMITATIONS 
Although performed according to a standardized protocol, personality traits of the 
physiotherapists who conducted the physical performance tests in Paper II might have 
influenced the results. Smoking habits were dependent on recall and personal declaration 
which may be a source of misclassification in Paper III. In the DFF study, the recruitment 
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rate was slow due to interruptions during the recruitment process, caused by personnel and 
workplace changes at the emergency ward. Although we did not consider the rate of refusal 
as high, this might be a source of bias. Comparisons between the DFF and OPRA cohort in 
Paper IV might be affected by differences in design and setup, and by the relatively small 
number of women with fracture and valid pQCT measurements in the OPRA cohort. In 
Paper V, the PHPT diagnosis was determined by repeated evaluations and a predetermined 
biochemical definition, confirmed by endocrinologists without affiliation to the study. 
However, this approach may be a source of selection bias. A major limitation is the lack of 
a control-group in this study. Validation of the findings in studies with a control group 
would be beneficial.  
6.2 CONCLUSIONS 
Several factors influence the risk of fracture in elderly women, and all factors need to be 
considered in order to perform an adequate fracture risk assessment. Mortality was increased 
among non-participants in the OPRA cohort when compared to those who participated, but it 
appeared that participants were representative in terms of fracture risk in general. 
Consideration of physical function and smoking habits appears to be advantageous in 
assessing fracture risk. Self-reported history of falls seems to be associated with increased 
risk of several fracture types, while reduced gait speed and a failed balance test appears to be 
associated with hip fracture. Smoking increases the risk of osteoporosis-related fractures, 
predominately vertebral fractures. Smoking cessation seems to decrease the risk of vertebral 
fractures but the risk of other fractures appears to be unaffected by smoking cessation. 
Trabecular and cortical bone reductions, as well as geometric alterations of the forearm, 
seems to be contributing factors in the pathogenesis of a distal forearm fracture. PTH and 
25OHD show signs of being weakly correlated with trabecular and cortical bone in the 
forearm. The prevalence of PHPT among postmenopausal women with a forearm fracture 
might be elevated and further evaluation following a distal forearm fracture would appear to 
be beneficial.   
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